Ibrance Joins Rival CDK4/6 Inhibitors In English Cancer Drugs Fund
Executive Summary
Pfizer’s Ibrance has won conditional reimbursement in England while more data is gathered to reduce some uncertainty.
You may also be interested in...
Lilly Undeterred By UK NICE Funding Blow For Second-Line Use Of Verzenios
Verzenios is one of three CDK4/6 inhibitors that are available via the Cancer Drugs Fund for use in previously treated patients with metastatic breast cancer, but it is the first for which health technology assessment body NICE has published a recommendation on routine commissioning.
NICE Draft Guidance: Rejects Keytruda In Head & Neck Cancer, Xospata In AML
A series of decisions on anticancer drugs from the UK’s NICE will act as a reminder to drug developers excited by potential breakthroughs that health technology assessment has become an exacting filter for new medicines to pass through.
How Sustainable Is England’s Cancer Drugs Fund?
The Cancer Drugs Fund has improved access to oncology drugs, but if it is to remain fit for purpose it will need to evolve.